These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25958022)

  • 1. Reply by Authors.
    J Urol; 2015 Aug; 194(2):599-600. PubMed ID: 25958022
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction: K. Ichihara, N. Masumori, F. Fukuta, T. Tsukamoto, A. Iwasawa and Y. Tanaka J Urol 2015; 193: 921-926.
    Singh S; Mavuduru RS; Bora GS
    J Urol; 2015 Aug; 194(2):598-9. PubMed ID: 25958019
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
    Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
    J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms.
    Matsukawa Y; Gotoh M
    Int J Urol; 2020 Jan; 27(1):85-86. PubMed ID: 31538373
    [No Abstract]   [Full Text] [Related]  

  • 5. Mirabegron the first β3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies.
    Chapple C
    BJU Int; 2014 Jun; 113(6):847-8. PubMed ID: 24905658
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
    Alcántara-Montero A
    Actas Urol Esp; 2016 Nov; 40(9):593-594. PubMed ID: 27126125
    [No Abstract]   [Full Text] [Related]  

  • 7. Mirabegron (Myrbetriq) for overactive bladder.
    Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

  • 9. Overactive bladder - pharmacological treatment.
    Sacomani CAR; Almeida FG; Silvinato A; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 May; 65(4):487-492. PubMed ID: 31066800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.
    Shin JH; Kim A; Choo MS
    Investig Clin Urol; 2017 Jul; 58(4):261-266. PubMed ID: 28681036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
    J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
    Chapple CR; Kaplan SA; Mitcheson D; Blauwet MB; Huang M; Siddiqui E; Khullar V
    Int J Urol; 2014 Oct; 21(10):960-7. PubMed ID: 25092441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirabegron: Pediatric First Approval.
    Keam SJ
    Paediatr Drugs; 2021 Jul; 23(4):411-415. PubMed ID: 34056686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?
    Serati M; Leone Roberti Maggiore U; Sorice P; Cantaluppi S; Finazzi Agrò E; Ghezzi F;
    Int Urogynecol J; 2017 Jul; 28(7):1033-1039. PubMed ID: 27942790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
    Yamaguchi O; Ikeda Y; Ohkawa S
    Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
    Eltink C; Lee J; Schaddelee M; Zhang W; Kerbusch V; Meijer J; van Marle S; Grunenberg N; Kowalski D; Drogendijk T; Moy S; Iitsuka H; van Gelderen M; Matsushima H; Sawamoto T
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):838-50. PubMed ID: 22943933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
    BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
    Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
    Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.